We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

82 hedge funds and large institutions have $93.4M invested in Compass Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

5% more funds holding

Funds holding: 78 → 82 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.23% less ownership

Funds ownership: 68.72% → 67.49% (-1.2%)

50% less capital invested

Capital invested by funds: $187M → $93.4M (-$93.8M)

Holders
82
Holders Change
+4
Holders Change %
+5.13%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
14
Increased
33
Reduced
18
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
MB
MPM BioImpact
Massachusetts
+$4.43M
2
Blackstone Inc
Blackstone Inc
New York
+$2.19M
3
BlackRock
BlackRock
New York
+$849K
4
Millennium Management
Millennium Management
New York
+$351K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$315K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.28M
2
CAM
Cormorant Asset Management
Massachusetts
-$5.15M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.86M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$562K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$112K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$22.4M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$11.1M – – –
Blackstone Inc
3
Blackstone Inc
New York
$7.69M +$2.19M +1,502,010 +24%
BlackRock
4
BlackRock
New York
$6.61M +$849K +581,171 +10%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$5.76M -$1.86M -1,276,558 -20%
RSCM
6
Rock Springs Capital Management
Maryland
$5.51M – – –
MB
7
MPM BioImpact
Massachusetts
$5.01M +$4.43M +3,033,684 +154%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.19M +$58.9K +40,332 +1%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$4.13M -$562K -384,762 -9%
VC
10
Vivo Capital
California
$3.56M – – –
BOCH
11
Blue Owl Capital Holdings
New York
$2.83M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$2.29M +$315K +215,348 +10%
CAM
13
Cormorant Asset Management
Massachusetts
$2.03M -$5.15M -3,529,477 -63%
State Street
14
State Street
Massachusetts
$1.86M +$49.6K +33,992 +2%
BBA
15
Baker Bros. Advisors
New York
$1.56M – – –
Northern Trust
16
Northern Trust
Illinois
$748K -$28.3K -19,347 -3%
MIM
17
Monashee Investment Management
Massachusetts
$500K – – –
Millennium Management
18
Millennium Management
New York
$434K +$351K +239,988 +124%
CM
19
CM Management
Florida
$310K – – –
N
20
Nuveen
North Carolina
$305K – – –
Charles Schwab
21
Charles Schwab
California
$286K +$67.2K +45,996 +19%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$284K +$45.9K +31,433 +12%
Citadel Advisors
23
Citadel Advisors
Florida
$268K +$180K +123,587 +86%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$244K -$112K -76,971 -24%
Goldman Sachs
25
Goldman Sachs
New York
$236K +$165K +112,794 +92%
1
2 3 4

CMPX Hedge Fund Activity: Q2 2024 in Review

82 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2024, worth a combined $93.4M — down 50% from $187M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new CMPX positions and 10 closed out — a net gain of 4 holders — while 33 added to existing stakes and 18 trimmed.

The largest buyer was MPM BioImpact, adding an estimated $4.43M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.28M sold.

  • 82 institutional investors held Compass Therapeutics (CMPX) as of Q2 2024, up from 78 in Q1 2024.
  • Funds reported $93.4M of Compass Therapeutics stock for Q2 2024, down 50% quarter-over-quarter.
  • 14 funds opened new Compass Therapeutics positions in Q2 2024 and 10 closed out, a net change of +4 holders.
  • The largest Compass Therapeutics buyer in Q2 2024 was MPM BioImpact, an estimated $4.43M added.
  • The largest Compass Therapeutics seller in Q2 2024 was Opaleye Management, an estimated $6.28M sold.

Based on aggregated 13F filings for Q2 2024.